Asgard Therapeutics is a private biotech company aiming to advance cancer immunotherapies by harnessing direct in-vivo cell fate reprogramming technologies. Formed as a spin-off from Lund University, in Sweden, we are pioneering a gene therapy approach based on our proprietary lead program AT-108, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard is building a multidisciplinary team that understands the value and opportunities of working in a startup based on a unique platform technology. We are looking for team members who are innovative and passionate about making a significant contribution to the cancer immunotherapy field, aiming at improving patients’ lives.
If this resonates with you, check our open positions below or email your CV and motivation letter to careers@asgardthx.com.